Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Eyre, TA"'
Publikováno v:
Clinical Interventions in Aging, Vol Volume 11, Pp 423-435 (2016)
John Willan,1 Toby A Eyre,1,2 Faye Sharpley,1 Caroline Watson,1 Andrew J King,1,3 Karthik Ramasamy1,4 1Department of Hematology, 2Early Phase Clinical Trial Unit, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Churchill H
Externí odkaz:
https://doaj.org/article/be51f22e0b1e4d7cb4f53b243e07e937
Autor:
Shah, NN, Zinzani, PL, Eyre, TA, Izutsu, K, Alencar, AJ, Patel, K, Munir, T, Tsai, DE, Wang, ML, Presenter, LYGN
Publikováno v:
In Hematology, Transfusion and Cell Therapy October 2023 45 Supplement 4:S359-S360
Autor:
Brown, JR, Woyach, JA, Patel, K, Eyre, TA, Cheah, Cy, Ghia, P, Jurczak, W, Abada, P, Wierda, WG, Presenter, GFPN
Publikováno v:
In Hematology, Transfusion and Cell Therapy October 2023 45 Supplement 4:S160-S161
Publikováno v:
In Hematology, Transfusion and Cell Therapy October 2023 45 Supplement 4:S162-S162
Autor:
Eyre, TA, Collins, GP, Gupta, A, Coupe, N, Sheikh, S, Whittaker, J, Wang, LM, Campo, L, Soilleux, E, Tysoe, F, Cousins, R, La Thangue, N, Folkes, LK, Stratford, MRL, Kerr, D, Middleton, MR
Background: In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462ba0397642be66177ba59f65148c1a
Autor:
Cuneo, A, Follows, G, Rigolin, GM, Piciocchi, A, Tedeschi, A, Trentin, L, Perez, AM, Coscia, M, Laurenti, L, Musuraca, G, Farina, L, Delgado, AR, Orlandi, EM, Galieni, P, Mauro, FR, Visco, C, Amendola, A, Billio, A, Marasca, R, Chiarenza, A, Meneghini, V, Ilariucci, F, Marchetti, M, Molica, S, Re, F, Gaidano, G, Gonzalez, M, Forconi, F, Ciolli, S, Cortelezzi, A, Montillo, M, Smolej, L, Schuh, A, Eyre, TA, Kennedy, B, Bowles, KM, Vignetti, M, de la Seam, J, Moreno, C, Foa, R, Ghia, P, GIMEMA, European Res Initiative CLL ERIC, UK CLL Forum
Publikováno v:
HAEMATOLOGICA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3da97517ae196f6a9a9be16c79c4c7bd
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3485
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3485
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Shah NN; Medical College of Wisconsin, Milwaukee, WI. nishah@mcw.edu., Wang M; MD Anderson Cancer Center, Houston, TX., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY., Patel K; Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Wierda WG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Ujjani CS; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford., Zinzani PL; Institute of Hematology 'Seragnoli' University of Bologna, Bologna., Alencar AJ; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Ghia P; Universita Vita-Salute San Raffaele, Milano, Italy; IRCCS Ospedale San Raffaele, Milano., Lamanna N; New York-Presbyterian Columbia University Medical Center, New York, NY., Hoffmann MS; Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL., Flinn I; Sarah Cannon Research Institute, Nashville, TN., Gerson JN; Lymphoma Program, Abramson Cancer Center, Philadelphia, PA., Ma S; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL., Coombs CC; University of California Irvine, Irvine, CA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Fakhri B; Division of Hematology at Stanford University School of Medicine, Stanford, CA., Kim WS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul., Barve MA; Mary Crowley Cancer Research Center, Dallas, TX., Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Munir T; Department of Haematology, St. James's University Hospital, Leeds., Thompson MC; Memorial Sloan Kettering Cancer Center, New York, NY., Tsai DE; Loxo@Lilly, Indianapolis, IN., Bao K; Loxo@Lilly, Indianapolis, IN., Cangemi NA; Loxo@Lilly, Indianapolis, IN., Kherani JF; Loxo@Lilly, Indianapolis, IN., Walgren RA; Loxo@Lilly, Indianapolis, IN., Han H; Loxo@Lilly, Indianapolis, IN., Ruppert AS; Eli Lilly and Company, Indianapolis, IN., Brown JR; Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Publikováno v:
Haematologica [Haematologica] 2024 Oct 03. Date of Electronic Publication: 2024 Oct 03.